Apellis Pharmaceuticals Inc

Apellis CEO’s January 2026 share sale is a tax‑driven routine move, not a red flag—investors see strong analyst support and a resilient stock price.

Apellis insider selling spikes: execs offload 30 % of holdings amid a 21 % share drop, raising caution on future prospects and regulatory hurdles.

Apellis insider Watson David O. buys 888 shares at $14.95, betting on the company’s bullish rally and upcoming data from the J.P. Morgan Healthcare Conference.